» Articles » PMID: 31551243

Comparison of Characteristics and Outcomes of Late Acute and NIH Chronic GVHD Between Japanese and White Patients

Abstract

Although differences in the incidence of chronic graft-versus-host disease (GVHD) across the races have been suggested, these have not been systematically investigated. This study compared the incidence, sites, severity, and outcomes of late acute GVHD and chronic GVHD according to National Institutes of Health (NIH) consensus criteria between Japanese (n = 413) and white (n = 708) patients after first allogeneic hematopoietic cell transplantation. Analysis was stratified according to bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT). Japanese patients, compared with white patients, had a similar incidence of late acute GVHD (BMT, 19% vs 16%; PBSCT, 19% vs 16%) but experienced more frequent liver late acute GVHD as defined by transaminase elevation (BMT, 79% vs 8%; PBSCT, 92% vs 33%) and less frequent gastrointestinal late acute GVHD (BMT, 11% vs 58%; PBSCT, 20% vs 68%). Japanese patients were more likely to discontinue systemic immunosuppression after late acute GVHD than white patients (hazard ratio, 3.68; 95% confidence interval, 1.96-6.94; < .001). Japanese patients, compared with white patients, had a lower incidence of chronic GVHD (BMT, 15% vs 30% [ = .002]; PBSCT, 37% vs 45% [ < .001]) and experienced more frequent chronic GVHD of the mouth, eyes, and liver and less frequent gastrointestinal chronic GVHD. The duration of immunosuppressive treatment of NIH chronic GVHD was similar between the races. These differences could not be entirely attributed to practice variation between the centers. This study shows that the incidence, affected sites, severity, and clinical outcomes of late acute GVHD and NIH chronic GVHD differ between Japanese and white patients.

Citing Articles

Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation.

Wada F, Iwasaki M, Hirayama M, Kawamura K, Kaida K, Doki N Leukemia. 2025; .

PMID: 39972117 DOI: 10.1038/s41375-025-02538-1.


Impact of stem cell source on secondary steroid for chronic GVHD after allogeneic hematopoietic cell transplantation.

Sanda K, Fuji S, Tada Y, Shingai Y, Kasahara H, Yuda S Int J Hematol. 2024; 121(1):100-109.

PMID: 39585531 DOI: 10.1007/s12185-024-03866-1.


Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study.

Shiratori S, Fukushima K, Onishi Y, Doki N, Goto T, Okada M Int J Hematol. 2024; 120(6):705-716.

PMID: 39361234 PMC: 11588829. DOI: 10.1007/s12185-024-03850-9.


Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD.

Akahoshi Y, Spyrou N, Hogan W, Ayuk F, DeFilipp Z, Weber D Blood Adv. 2023; 7(16):4479-4491.

PMID: 37315175 PMC: 10440469. DOI: 10.1182/bloodadvances.2023009885.


Novel Treatment for Graft-versus-Host Disease.

Inamoto Y, Zeiser R, Chan G Blood Cell Ther. 2023; 4(4):101-109.

PMID: 36714067 PMC: 9847314. DOI: 10.31547/bct-2021-022.


References
1.
Bensinger W, Martin P, Storer B, Clift R, Forman S, Negrin R . Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001; 344(3):175-81. DOI: 10.1056/NEJM200101183440303. View

2.
Lee S, Vogelsang G, Flowers M . Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003; 9(4):215-33. DOI: 10.1053/bbmt.2003.50026. View

3.
Lin M, Storer B, Martin P, Tseng L, Gooley T, Chen P . Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med. 2003; 349(23):2201-10. DOI: 10.1056/NEJMoa022060. View

4.
Oh H, Loberiza Jr F, Zhang M, Ringden O, Akiyama H, Asai T . Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2004; 105(4):1408-16. DOI: 10.1182/blood-2004-06-2385. View

5.
Sorror M, Maris M, Storb R, Baron F, Sandmaier B, Maloney D . Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106(8):2912-9. PMC: 1895304. DOI: 10.1182/blood-2005-05-2004. View